The Role of the Pathologist in Renal Cell Carcinoma Management

Sayed Matar; Nourhan El Ahmar; Yasmin Nabil Laimon; Fatme Ghandour; Sabina Signoretti

doi:10.1016/j.hoc.2023.04.014

The Role of the Pathologist in Renal Cell Carcinoma Management

Hematol Oncol Clin North Am. 2023 Oct;37(5):849-862. doi: 10.1016/j.hoc.2023.04.014. Epub 2023 May 29.

Authors

Sayed Matar¹, Nourhan El Ahmar¹, Yasmin Nabil Laimon¹, Fatme Ghandour¹, Sabina Signoretti²

Affiliations

¹ Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
² Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Merkin Building, 415 Main Street, Cambridge, MA 02142, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: [email protected].

PMID: 37258353
DOI: 10.1016/j.hoc.2023.04.014

Abstract

Recent advances in our understanding of the molecular alterations underlying different types of renal cell carcinoma (RCC), as well as the implementation of immune checkpoint inhibitors in the treatment of patients with advanced disease, have significantly expanded the role of pathologists in the management of RCC patients and in the identification of predictive biomarkers that can guide patient treatment. In this chapter, we examine pathologists' evolving role in patient care and the development of precision medicine strategies for RCC.

Keywords: Biomarker; Classification; Immune checkpoints; Immunohistochemistry; PD-1; PD-L1; Pathology; Renal cell carcinoma.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

B7-H1 Antigen
Biomarkers
Biomarkers, Tumor / genetics
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / genetics
Humans
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / genetics
Pathologists

Substances

Biomarkers
B7-H1 Antigen
Biomarkers, Tumor

Abstract

Publication types

MeSH terms

Substances

Grants and funding